PLEKHA8

Across TCGA pan-cancer cohorts, PLEKHA8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHA8 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PLEKHA8 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLEKHA8 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

UCEC, PDAC, and GBM are the cancer types where PLEKHA8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	1.000	0.457	.016	12	view →
PDAC	DFS	Quartile	All	0.929	0.317	.024	3	view →
GBM	OS	Median	All	0.874	0.754	.006	2	view →
LUAD	OS	Median	III,IV	1.000	0.281	.040	2	view →
CCRCC	OS	Median	II,III,IV	0.674	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHA8–UCEC (OS)

Open the UCEC breakdown →